Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
11.27
+0.09 (0.81%)
Oct 23, 2026, 3:04 PM CST
SHE:002365 Revenue
Qianjiang Yongan Pharmaceutical had revenue of 327.81M CNY in the quarter ending June 30, 2026, with 67.06% growth. This brings the company's total for the last twelve months to 979.49M, up 25.52% year-over-year. In the year 2025, Qianjiang Yongan Pharmaceutical had annual revenue of 783.17M, down -6.63%. That makes Qianjiang Yongan Pharmaceutical the 19,796th largest company in the world by revenue and 3,628th in China.
Revenue (ttm)
979.49M
Revenue Growth
+25.52%
P/S Ratio
3.33
Revenue / Employee
1.07M
Employees
912
Market Cap
3.26B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:002365 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 783.17M | -55.65M | -6.63% |
| Dec 31, 2024 | 838.81M | -134.08M | -13.78% |
| Dec 31, 2023 | 972.89M | -489.56M | -33.48% |
| Jan 1, 2023 | 1.46B | -102.96M | -6.58% |
| Jan 1, 2022 | 1.57B | 392.56M | 33.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 23.66B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| ChengDu ShengNuo Biotec | 911.15M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Nanjing Hicin Pharmaceutical | 726.62M |